Status:
COMPLETED
Spironolactone in Covid-19 Induced ARDS
Lead Sponsor:
Istanbul University - Cerrahpasa
Conditions:
Respiratory Distress Syndrome, Adult
Eligibility:
All Genders
18+ years
Brief Summary
This study intended to evaluate the effects of commonly used diuretic, spironolactone, on oxygenation in covid-19 ARDS patients.
Eligibility Criteria
Inclusion
- Hemodynamically stable
- Hypoxemia, i.e. p/f \<150
- Admitted to ICU within 48 hours
- Not moribund has a life expectancy greater than 24 hours
Exclusion
- Age criteria
- Pregnancy
- Unwillingness to participate
Key Trial Info
Start Date :
May 5 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 5 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04345887
Start Date
May 5 2020
End Date
July 5 2020
Last Update
October 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istanbul University-Cerrahpaşa
Istanbul, Turkey (Türkiye)